- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Clinical and Developmental Immunology
Volume 2012 (2012), Article ID 981519, 7 pages
Seizures in Primary Antiphospholipid Syndrome: The Relevance of Smoking to Stroke
1Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, 01246-903 São Paulo, SP, Brazil
2Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de Campinas, Campinas, SP, Brazil
Received 20 November 2011; Accepted 14 January 2012
Academic Editor: Clelia M. Riera
Copyright © 2012 Jozélio Freire de Carvalho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- D. Erkan and M. D. Lockshin, “New approaches for managing antiphospholipid syndrome,” Nature Clinical Practice Rheumatology, vol. 5, no. 3, pp. 160–170, 2009.
- G. R. V. Hughes, “Thrombosis, abortion, cerebral disease, and the lupus anticoagulant,” British Medical Journal, vol. 287, no. 6399, pp. 1088–1089, 1983.
- G. Ruiz-Irastorza, M. Crowther, W. Branch, and M. A. Khamashta, “Antiphospholipid syndrome,” The Lancet, vol. 376, no. 9751, pp. 1498–1509, 2010.
- D. Erkan, M. J. Harrison, R. Levy et al., “Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals,” Arthritis and Rheumatism, vol. 56, no. 7, pp. 2382–2391, 2007.
- R. Cervera, J.-C. Piette, J. Font et al., “Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients,” Arthritis and Rheumatism, vol. 46, no. 4, pp. 1019–1027, 2002.
- G. Sanna, M. L. Bertolaccini, M. J. Cuadrado, M. A. Khamashta, and G. R. V. Hughes, “Central nervous system involvement in the antiphospholipid (Hughes) syndrome,” Rheumatology, vol. 42, no. 2, pp. 200–213, 2003.
- C. E. M. Rodrigues, J. F. Carvalho, and Y. Shoenfeld, “Neurological manifestations of antiphospholipid syndrome,” European Journal of Clinical Investigation, vol. 40, no. 4, pp. 350–359, 2010.
- J. Chapman, M. Cohen-Armon, Y. Shoenfeld, and A. D. Korczyn, “Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes,” Lupus, vol. 8, no. 2, pp. 127–133, 1999.
- Y. Shoenfeld, S. Lev, I. Blatt et al., “Features associated with epilepsy in the antiphospholipid syndrome,” Journal of Rheumatology, vol. 31, no. 7, pp. 1344–1348, 2004.
- H. H. Liou, C. R. Wang, H. C. Chou et al., “Anticardiolipin antisera from lupus patients with seizures reduce a GABA receptor-mediated chloride current in snail neurons,” Life Sciences, vol. 54, no. 15, pp. 1119–1125, 1994.
- L. Cocito, E. Favale, and L. Reni, “Epileptic seizures in cerebral arterial occlusive disease,” Stroke, vol. 13, no. 2, pp. 189–195, 1982.
- R. A. Asherson, M. A. Khamashta, A. Gil et al., “Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome,” American Journal of Medicine, vol. 86, no. 4, pp. 391–399, 1989.
- S. Miyakis, M. D. Lockshin, T. Atsumi et al., “International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS),” Journal of Thrombosis and Haemostasis, vol. 4, no. 2, pp. 295–306, 2006.
- I. M. Benseñor, P. A. Lotufo, P. R. Menezes, and M. Scazufca, “Subclinical hyperthyroidism and dementia: the Sao Paulo ageing & Health study (SPAH),” BMC Public Health, vol. 10, p. 298, 2010.
- “The IDF consensus worldwide definition of the metabolic syndrome,” International Diabetes Federation, 2006, http://www.idf.org/metabolic_syndrome_def.pdf.
- W. T. Blume, H. O. Lüders, E. Mizrahi, C. Tassinari, W. Van Emde Boas, and J. Engel Jr, “Glossary of descriptive terminology for ictal semiology: report of the ILAE Task Force on classification and terminology,” Epilepsia, vol. 42, no. 9, pp. 1212–1218, 2001.
- R. S. Fisher, W. van Emde Boas, W. Blume et al., “Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE),” Epilepsia, vol. 46, no. 4, pp. 470–472, 2005.
- S. Appenzeller, F. Cendes, and L. T. L. Costallat, “Epileptic seizures in systemic lupus erythematosus,” Neurology, vol. 63, no. 10, pp. 1808–1812, 2004.
- S. S. Pierangeli and E. N. Harris, “A protocol for determination of anticardiolipin antibodies by ELISA,” Nature Protocols, vol. 3, no. 5, pp. 840–848, 2008.
- F. Wisloff, E. M. Jacobsen, and S. Liestol, “Laboratory diagnosis of the antiphospholipid syndrome,” Thrombosis Research, vol. 108, no. 5-6, pp. 263–271, 2002.
- R. H. Esparza, T. Swaak, L. Aarden, and R. Smeenk, “Complement-fixing antibodies to dsDNA detected by the immunofluorescence technique on Crithidia luciliae. A critical appraisal,” Journal of Rheumatology, vol. 12, no. 6, pp. 1109–1117, 1985.
- E. M. Tan and C. Peebles, “Quantitation of antibodies to Sm antigen and nuclear ribonucleoprotein by hemagglutination,” in Manual of Clinical Immunology, N. R. Rose and H. Friedman, Eds., pp. 866–870, American Society of Microbiology, Washington, DC, USA, 2nd edition, 1980.
- B. A. Dworetzky, E. B. Bromfield, M. K. Townsend, and J. H. Kang, “A prospective study of smoking, caffeine, and alcohol as risk factors for seizures or epilepsy in young adult women: data from the Nurses' Health Study II,” Epilepsia, vol. 51, no. 2, pp. 198–205, 2010.
- C. M. de Fiebre and A. C. Collins, “Decreased sensitivity to nicotine-induced seizures as a consequence of nicotine pretreatment in long-sleep and short-sleep mice,” Alcohol, vol. 5, no. 1, pp. 55–61, 1988.
- R. S. Broide, R. Salas, D. Ji et al., “Increased sensitivity to nicotine-induced seizures in mice expressing the L250t α7 nicotinic acetylcholine receptor mutation,” Molecular Pharmacology, vol. 61, no. 3, pp. 695–705, 2002.
- R. W. Sanders, K. D. Katz, J. Suyama et al., “Seizure during hyperbaric oxygen therapy for carbon monoxide toxicity: a case series and five-year experience,” Journal of Emergency Medicine, 2009.
- M. R. Arbuckle, M. T. McClain, M. V. Rubertone et al., “Development of autoantibodies before the clinical onset of systemic lupus erythematosus,” New England Journal of Medicine, vol. 349, no. 16, pp. 1526–1533, 2003.
- A. R. Ribeiro and J. F. Carvalho, “Traditional risk factors for cardiovascular disease in primary antiphospholipid syndrome (APS) when compared with secondary APS: a study with 96 patients,” Acta Reumatologica Portuguesa, vol. 35, no. 1, pp. 36–41, 2010.
- R. Gualtierotti, M. Biggioggero, and P. L. Meroni, “Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome,” Clinical Reviews in Allergy and Immunology. In press.
- P. M. Moore and R. P. Lisak, “Systemic lupus erythematosus: immunopathogenesis of neurologic dysfunction,” Springer Seminars in Immunopathology, vol. 17, no. 1, pp. 43–60, 1995.